ZLWT-37

• UNSPSC Description:

  ZLWT-37 is a potent, orally active CDKs inhibitor with IC50 values of 0.002 μM and 0.054 μM against CDK9 and CDK2, respectively. ZLWT-37 induces apoptosis and arrests the cell cycle in the G2/M phase in HCT116 cells[1].

• Target Antigen:

  Apoptosis; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/zlwt-37.html

• Solubility:

  10 mM in DMSO

• Smiles:

  N[C@H]1CCN(C1)C2=C3CCCCC3=NC4=C2C=C(C=C4)C5=CC=NC(NC(C6CC6)=O)=C5.Cl

• Molecular Weight:

  464.00

• References & Citations:

  [1]Liu W, et al. Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property. Bioorg Chem. 2022 Sep;126:105875.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2813347-44-1